X

Trial Profile

A Phase Ib/II trial of SB 11285 in liver cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SB 11285 (Primary)
Indications Liver cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Apr 2019 According to a Spring Bank Pharmaceuticals media release, the company is on track to submit an IND for SB-11285 in the second quarter of 2019 and, if the IND is approved, will initiate the trial thereafter.
11 Mar 2019 According to a Spring Bank Pharmaceuticals media release, the company is planning to initate this study in mid 2019.
01 Nov 2018 According to a Spring Bank Pharmaceuticals media release, the company plans to initiate this trial in 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com